WO2024020520A3 - Enzyme compositions, steroid derivatives, enzyme inhibitors, and methods of making same for pharmaceutical applications - Google Patents

Enzyme compositions, steroid derivatives, enzyme inhibitors, and methods of making same for pharmaceutical applications Download PDF

Info

Publication number
WO2024020520A3
WO2024020520A3 PCT/US2023/070652 US2023070652W WO2024020520A3 WO 2024020520 A3 WO2024020520 A3 WO 2024020520A3 US 2023070652 W US2023070652 W US 2023070652W WO 2024020520 A3 WO2024020520 A3 WO 2024020520A3
Authority
WO
WIPO (PCT)
Prior art keywords
enzyme
methods
making same
pharmaceutical applications
steroid derivatives
Prior art date
Application number
PCT/US2023/070652
Other languages
French (fr)
Other versions
WO2024020520A2 (en
Inventor
Francis Yoshimoto
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of WO2024020520A2 publication Critical patent/WO2024020520A2/en
Publication of WO2024020520A3 publication Critical patent/WO2024020520A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The present disclosure provides for a synthetic strategy to incorporate a C12α-hydroxy group from the methylene (-CH2-) in a steroid backbone, combining synthetic chemistry and enzymology techniques to develop a selective inhibitor for cytochrome P450 8B1, and developing a selective P450 8B1 inhibitor, which can be used as a tool to study P450 8B1 and treat health issues.
PCT/US2023/070652 2022-07-20 2023-07-20 Enzyme compositions, steroid derivatives, enzyme inhibitors, and methods of making same for pharmaceutical applications WO2024020520A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263390966P 2022-07-20 2022-07-20
US63/390,966 2022-07-20

Publications (2)

Publication Number Publication Date
WO2024020520A2 WO2024020520A2 (en) 2024-01-25
WO2024020520A3 true WO2024020520A3 (en) 2024-03-28

Family

ID=89618526

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/070652 WO2024020520A2 (en) 2022-07-20 2023-07-20 Enzyme compositions, steroid derivatives, enzyme inhibitors, and methods of making same for pharmaceutical applications

Country Status (1)

Country Link
WO (1) WO2024020520A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110178065A1 (en) * 2010-01-15 2011-07-21 Biomarin Pharmaceutical Inc. Novel cyp17 inhibitors
WO2012083112A2 (en) * 2010-12-16 2012-06-21 Biomarin Pharmaceutical Inc. Cyp11b, cyp17, and/or cyp21 inhibitors
US20140088053A1 (en) * 2011-03-25 2014-03-27 UNIVERSITé LAVAL INHIBITORS OF 17Beta-HSD1, 17Beta-HSD3 AND 17Beta-HSD10

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110178065A1 (en) * 2010-01-15 2011-07-21 Biomarin Pharmaceutical Inc. Novel cyp17 inhibitors
WO2012083112A2 (en) * 2010-12-16 2012-06-21 Biomarin Pharmaceutical Inc. Cyp11b, cyp17, and/or cyp21 inhibitors
US20140088053A1 (en) * 2011-03-25 2014-03-27 UNIVERSITé LAVAL INHIBITORS OF 17Beta-HSD1, 17Beta-HSD3 AND 17Beta-HSD10

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHUNG EUNHEE; OFFEI SAMUEL D.; AONDO JIA U-TER; ESTEVEZ JUAN; PEREZ YESSENIA; ARMAN HADI D.; YOSHIMOTO FRANCIS K.: "A synthesis of a rationally designed inhibitor of cytochrome P450 8B1, a therapeutic target to treat obesity", STEROIDS, vol. 178, 27 December 2021 (2021-12-27), US , pages 1 - 10, XP086950419, ISSN: 0039-128X, DOI: 10.1016/j.steroids.2021.108952 *
F. PETER GUENGERICH: "Intersection of the Roles of Cytochrome P450 Enzymes with Xenobiotic and Endogenous Substrates: Relevance to Toxicity and Drug Interactions", CHEMICAL RESEARCH IN TOXICOLOGY, vol. 30, no. 1, 17 January 2017 (2017-01-17), US , pages 2 - 12, XP093154948, ISSN: 0893-228X, DOI: 10.1021/acs.chemrestox.6b00226 *
JINGHAN LIU , SAMUEL D. OFFEI , FRANCIS K. YOSHIMOTO , EMILY E. SCOTT: "Pyridine-containing substrate analogs are restricted from accessing the human cytochrome P450 8B1 active site by tryptophan 281", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 299, no. 4, 1 April 2023 (2023-04-01), US , pages 1 - 10, XP093154954, ISSN: 0021-9258, DOI: 10.1016/j.jbc.2023.103032 *

Also Published As

Publication number Publication date
WO2024020520A2 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
MY173184A (en) Tin hard mask and etch residue removal
WO2022035911A3 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
MX2009006227A (en) Aspartyl protease inhibitors containing a tricyclic ring system.
WO2012031174A3 (en) Enhancement of potato tuber sprouting inhibitors using various combinations of agents
NO20050290L (en) Novel tetrahydropyridine derivatives as renin inhibitors
WO2007067836A3 (en) Substituted pyrazole compounds useful as soluble epoxide hydrolase inhibitors
IL199999A0 (en) Peroxide activated oxometalate based formulations for removal of etch residue
WO2006066109A3 (en) Hydroxysteroid dehydrogenase inhibitors
ATE375088T1 (en) PREPARATIONS FOR PRESERVING FRUITS AND VEGETABLES
MX2022014007A (en) Compounds as bcl-2 inhibitors.
NO20055623L (en) Azabicyklononenderivater
MX2022010944A (en) Eif4e inhibitors and uses thereof.
WO2007102127A3 (en) New amines
TW200738714A (en) New secondary amines
WO2020247701A3 (en) Inhibitors of sarm1
WO2024020520A3 (en) Enzyme compositions, steroid derivatives, enzyme inhibitors, and methods of making same for pharmaceutical applications
WO2008100280A3 (en) Antimicrobial compositions and methods for treating packaged food products
WO2007099509A3 (en) Primary amines as renin inhibitors
CR20230362A (en) Cdk2 inhibitors and methods of using the same
TW200628468A (en) Bicyclononene derivatives
WO2022221528A3 (en) Kras g12c inhibitors
WO2008065485A3 (en) Stable pharmaceutical compositions of a calcium channel blocker and an ace inhibitor
WO2005053725A3 (en) Cancer treatment
AU2021315475A8 (en) Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza
KR102433728B9 (en) FABP4 A Composition for Facilitating Ciliogenesis Comprising Novel FABP4 Inhibitors as Active Ingredients

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23843905

Country of ref document: EP

Kind code of ref document: A2